Vaxcyte (NASDAQ:PCVX) EVP Sells $79,399.68 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,334 shares of Vaxcyte stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $59.52, for a total value of $79,399.68. Following the completion of the sale, the executive vice president directly owned 145,435 shares in the company, valued at $8,656,291.20. This represents a 0.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Trading Down 1.4%

Shares of NASDAQ:PCVX traded down $0.85 on Wednesday, reaching $59.51. 1,195,242 shares of the company were exchanged, compared to its average volume of 1,369,661. The company has a 50-day moving average of $58.41 and a 200-day moving average of $56.32. The firm has a market cap of $8.86 billion, a price-to-earnings ratio of -7.80 and a beta of 1.22. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the company earned ($1.22) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Institutional Trading of Vaxcyte

Institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC increased its holdings in shares of Vaxcyte by 4.0% during the 2nd quarter. Hsbc Holdings PLC now owns 4,151 shares of the company’s stock worth $241,000 after buying an additional 159 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the period. Meeder Advisory Services Inc. grew its position in Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock valued at $484,000 after acquiring an additional 231 shares during the period. IFP Advisors Inc increased its stake in Vaxcyte by 72.8% during the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after acquiring an additional 236 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Vaxcyte by 27.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,344 shares of the company’s stock worth $78,000 after acquiring an additional 291 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.